Mechanism
The HPO axis operates via pulsatile GnRH from the hypothalamus → LH/FSH from pituitary → estrogen/progesterone from ovaries. Exogenous androgens and SARMs disrupt this via negative feedback at the hypothalamic and pituitary level — suppressing GnRH pulsatility and therefore LH/FSH. With reduced LH, follicular development is impaired, ovulation may not occur, and progesterone production from the corpus luteum is insufficient. The menstrual cycle requires this entire sequence to function. Even compounds considered "mild" in male contexts (Ostarine at 15mg, Anavar at 10mg) can suppress HPO function in women because female HPO feedback sensitivity to androgens is significantly greater than male.
Signs & Symptoms
- Cycle becoming lighter and shorter within the first 2–4 weeks of compound use
- Spotting mid-cycle or premenstrual spotting beginning during compound use
- Cycle length extending beyond normal (from 28 days to 35+ days)
- Complete absence of period during compound use
- Period not returning within 6 weeks of stopping compound
- Absence of premenstrual symptoms that were previously present — may indicate anovulation
Stages
Prevention
- Use the lowest effective dose — reduce suppression duration and depth
- Maximum 6–8 week cycles — shorter cycles = faster HPO recovery
- Do not stack multiple androgenic or SARM compounds
- Track cycle from before starting compound — know your baseline
- If cycle disrupts — respond immediately, do not wait to see if it corrects
Management Protocol
- Cycle absent during compound use — reduce dose by half, reassess in 2 weeks; if still absent, cease compound
- Post-cycle cycle non-return within 6 weeks — increase calories, reduce training volume, ensure sleep is adequate
- Post-cycle cycle non-return beyond 8 weeks — gynecologist consultation: LH, FSH, estradiol, progesterone panel
- Support HPO recovery: vitamin E 400 IU/day, zinc 25mg, adequate dietary fat and carbohydrates
- Do not use OCP to "fix" — this masks HPO recovery without treating it
Risk by Compound
| Compound | Risk Level | Notes |
|---|---|---|
| Testosterone | Very High | Profound HPO suppression. Cycle loss within weeks. |
| Anavar 5–10mg | Low-Medium | Mild suppression. Most women retain cycle at these doses. |
| Anavar above 15mg | High | HPO suppression becomes significant above female dose ceiling. |
| Ostarine 10–15mg | Low | Mild suppression. Monitor cycle. |
| Clenbuterol | Low-Medium | Not androgenic but high cortisol/norepinephrine effect can disrupt cycle via HPA-HPO crosstalk. |
Your menstrual cycle is a vital sign. When it disappears on a compound, your HPO axis is telling you the dose is too high or the duration is too long. The cycle is not optional — it is the indicator of overall hormonal health. Any compound that makes it disappear is working against your long-term health, even if it is improving your body composition in the short term.